KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Cash (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Change in Cash data on record, last reported at $65.8 million in Q4 2025.

  • For Q4 2025, Change in Cash fell 66.19% year-over-year to $65.8 million; the TTM value through Dec 2025 reached -$1.0 billion, down 212.62%, while the annual FY2025 figure was -$1.0 billion, 212.62% down from the prior year.
  • Change in Cash reached $65.8 million in Q4 2025 per JAZZ's latest filing, down from $136.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $1.0 billion in Q1 2021 and bottomed at -$1.2 billion in Q2 2021.
  • Average Change in Cash over 5 years is $16.7 million, with a median of $59.6 million recorded in 2023.
  • The widest YoY moves for Change in Cash: up 1518.11% in 2021, down 1527.71% in 2021.
  • A 5-year view of Change in Cash shows it stood at -$80.3 million in 2021, then soared by 152.44% to $42.1 million in 2022, then surged by 305.04% to $170.6 million in 2023, then increased by 14.13% to $194.7 million in 2024, then crashed by 66.19% to $65.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $65.8 million in Q4 2025, $136.2 million in Q3 2025, and -$672.1 million in Q2 2025.